BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32276618)

  • 1. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
    Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
    PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
    Maokola W; Ngowi B; Lawson L; Robert M; Mahande M; Todd J; Msuya S
    Int J Infect Dis; 2021 Feb; 103():562-567. PubMed ID: 33276111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
    Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
    BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.
    Maokola WM; Ngowi BJ; Mahande MJ; Todd J; Robert M; Msuya SE
    PLoS One; 2021; 16(7):e0254082. PubMed ID: 34255776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
    Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
    PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
    Shayo GA; Moshiro C; Aboud S; Bakari M; Mugusi FM
    BMC Infect Dis; 2015 Aug; 15():368. PubMed ID: 26306511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.
    Reddy MM; Thekkur P; Ramya N; Kamath PBT; Shastri SG; Kumar RBN; Chinnakali P; Nirgude AS; Rangaraju C; Somashekar N; Kumar AMV
    Glob Health Action; 2020; 13(1):1704540. PubMed ID: 31937200
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
    Nyarubamba RF; Silumbwe A; Jacobs C; Maritim P; Mdoe P; Zulu JM
    BMC Infect Dis; 2022 Nov; 22(1):884. PubMed ID: 36434517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
    Ngugi SK; Muiruri P; Odero T; Gachuno O
    BMC Infect Dis; 2020 Apr; 20(1):294. PubMed ID: 32664847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study.
    Denegetu AW; Dolamo BL
    BMC Public Health; 2014 Jan; 14():52. PubMed ID: 24438508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
    PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    Nabity SA; Gunde LJ; Surie D; Shiraishi RW; Kirking HL; Maida A; Auld AF; Odo M; Jahn A; Nyirenda RK; Oeltmann JE
    PLoS One; 2021; 16(4):e0248115. PubMed ID: 33793577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.
    Yirdaw KD; Jerene D; Gashu Z; Edginton ME; Kumar AM; Letamo Y; Feleke B; Teklu AM; Zewdu S; Weiss B; Ruff A
    PLoS One; 2014; 9(8):e104557. PubMed ID: 25105417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid preventive therapy completion between July-September 2019: A comparison across HIV differentiated service delivery models in Uganda.
    Mugenyi L; Namuwenge PM; Ouma S; Bakashaba B; Nanfuka M; Zech J; Agaba C; Mijumbi Ojok A; Kaliba F; Bossa Kato J; Opito R; Miya Y; Katureebe C; Hirsch-Moverman Y
    PLoS One; 2024; 19(1):e0296239. PubMed ID: 38166009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Isoniazid Preventive Therapy and Incidence of Tuberculosis among People Living with Human Immunodeficiency Virus Seeking Care in an Anti-retroviral Therapy Center, Puducherry.
    Kannusamy S; Sahu SK; Udayashankar C; Sarveswaran G; Roy G
    Indian J Public Health; 2024 Jan; 68(1):15-20. PubMed ID: 38847627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.